News | June 30, 2025
Biocon Biologics expands insulin access in Malaysia
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
10+ emerging markets, Japan & ANZ transition in final phase
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated
